Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

医学 伊库利珠单抗 双盲 乙酰胆碱受体 内科学 安慰剂 重症肌无力 抗体 耐火材料(行星科学) 胃肠病学 免疫学 受体 补体系统 天体生物学 物理 病理 替代医学
作者
James F. Howard,Kimiaki Utsugisawa,Michael G Benatar,Hiroyuki Murai,Richard J. Barohn,Isabel Illa,Saiju Jacob,John Vissing,Ted M. Burns,John T. Kissel,Srikanth Muppidi,Richard J. Nowak,Fanny O’Brien,Jingjing Wang,Renato Mantegazza,Claudio Gabriel Mazia,Miguel Wilken,Carolina Ortea,Juliet Saba,Marcelo Francisco Rugiero
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:16 (12): 976-986 被引量:846
标识
DOI:10.1016/s1474-4422(17)30369-1
摘要

Complement is likely to have a role in refractory generalised myasthenia gravis, but no approved therapies specifically target this system. Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis. We further assessed the efficacy and safety of eculizumab in this patient population in a phase 3 trial.We did a phase 3, randomised, double-blind, placebo-controlled, multicentre study (REGAIN) in 76 hospitals and specialised clinics in 17 countries across North America, Latin America, Europe, and Asia. Eligible patients were aged at least 18 years, with a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of 6 or more, Myasthenia Gravis Foundation of America (MGFA) class II-IV disease, vaccination against Neisseria meningitides, and previous treatment with at least two immunosuppressive therapies or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 months without symptom control. Patients with a history of thymoma or thymic neoplasms, thymectomy within 12 months before screening, or use of intravenous immunoglobulin or plasma exchange within 4 weeks before randomisation, or rituximab within 6 months before screening, were excluded. We randomly assigned participants (1:1) to either intravenous eculizumab or intravenous matched placebo for 26 weeks. Dosing for eculizumab was 900 mg on day 1 and at weeks 1, 2, and 3; 1200 mg at week 4; and 1200 mg given every second week thereafter as maintenance dosing. Randomisation was done centrally with an interactive voice or web-response system with patients stratified to one of four groups based on MGFA disease classification. Where possible, patients were maintained on existing myasthenia gravis therapies and rescue medication was allowed at the study physician's discretion. Patients, investigators, staff, and outcome assessors were masked to treatment assignment. The primary efficacy endpoint was the change from baseline to week 26 in MG-ADL total score measured by worst-rank ANCOVA. The efficacy population set was defined as all patients randomly assigned to treatment groups who received at least one dose of study drug, had a valid baseline MG-ADL assessment, and at least one post-baseline MG-ADL assessment. The safety analyses included all randomly assigned patients who received eculizumab or placebo. This trial is registered with ClinicalTrials.gov, number NCT01997229.Between April 30, 2014, and Feb 19, 2016, we randomly assigned and treated 125 patients, 62 with eculizumab and 63 with placebo. The primary analysis showed no significant difference between eculizumab and placebo (least-squares mean rank 56·6 [SEM 4·5] vs 68·3 [4·5]; rank-based treatment difference -11·7, 95% CI -24·3 to 0·96; p=0·0698). No deaths or cases of meningococcal infection occurred during the study. The most common adverse events in both groups were headache and upper respiratory tract infection (ten [16%] for both events in the eculizumab group and 12 [19%] for both in the placebo group). Myasthenia gravis exacerbations were reported by six (10%) patients in the eculizumab group and 15 (24%) in the placebo group. Six (10%) patients in the eculizumab group and 12 (19%) in the placebo group required rescue therapy.The change in the MG-ADL score was not statistically significant between eculizumab and placebo, as measured by the worst-rank analysis. Eculizumab was well tolerated. The use of a worst-rank analytical approach proved to be an important limitation of this study since the secondary and sensitivity analyses results were inconsistent with the primary endpoint result; further research into the role of complement is needed.Alexion Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
YANG_2025完成签到,获得积分10
刚刚
molihuakai的应助被科研通管家采纳,获得10
1秒前
CipherSage的应助被小王采纳,获得10
1秒前
李爱国的应助被科研通管家采纳,获得10
1秒前
所所的应助被科研通管家采纳,获得10
1秒前
因心发布了新的文献求助10
1秒前
大个的应助被科研通管家采纳,获得10
1秒前
蓝天的应助被科研通管家采纳,获得10
1秒前
pluto的应助被科研通管家采纳,获得50
1秒前
慕青的应助被科研通管家采纳,获得10
1秒前
所所的应助被科研通管家采纳,获得10
1秒前
Maestro_S的应助被科研通管家采纳,获得10
2秒前
小蘑菇的应助被科研通管家采纳,获得20
2秒前
2秒前
小二郎的应助被科研通管家采纳,获得50
2秒前
无花果的应助被科研通管家采纳,获得10
2秒前
香蕉觅云的应助被科研通管家采纳,获得10
2秒前
2秒前
2秒前
知夏发布了新的文献求助10
2秒前
汉堡包的应助被科研通管家采纳,获得10
2秒前
2秒前
深情安青的应助被科研通管家采纳,获得10
3秒前
dakjdia发布了新的文献求助10
3秒前
3秒前
好好活着的应助被科研通管家采纳,获得10
3秒前
好好活着的应助被科研通管家采纳,获得10
3秒前
慕青的应助被科研通管家采纳,获得10
3秒前
3秒前
4秒前
4秒前
范小羽发布了新的文献求助10
4秒前
顾矜的应助被希希不吃西红柿采纳,获得10
4秒前
5566妈完成签到,获得积分10
5秒前
Tams1n发布了新的文献求助10
5秒前
脑洞疼的应助被wyr采纳,获得10
5秒前
852的应助被张境文采纳,获得10
5秒前
jj完成签到,获得积分10
5秒前
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8171344
求助须知:如何正确求助?哪些是违规求助? 9564071
关于积分的说明 21773470
捐赠科研通 7762877
什么是DOI,文献DOI怎么找? 3430889
关于科研通互助平台的介绍 2554776
邀请新用户注册赠送积分活动 2475847